BRÈVE

sur Bausch Health Companies Inc. (NASDAQ:BHC)

Federal Court Upholds Ruling Against Norwich’s ANDA for XIFAXAN Until 2029

Bausch Health Companies Inc., alongside its gastroenterology arm Salix Pharmaceuticals, announced that the U.S. Court of Appeals for the Federal Circuit has affirmed earlier court decisions that prevent the FDA approval of Norwich Pharmaceuticals, Inc.’s abbreviated new drug application (ANDA) for XIFAXAN (rifaximin) 550 mg until October 2, 2029. This decision follows the affirmation of a May 2023 U.S. District Court ruling and an August 2022 decision that invalidated certain patents of XIFAXAN but concurrently barred Norwich’s ANDA approval.

Thomas J. Appio, CEO of Bausch Health, expressed satisfaction with the maintenance of the judgment against Norwich’s application, emphasizing the company’s commitment to defending its intellectual property and ensuring patient safety for users of XIFAXAN. Despite the invalidation of some patents related to the drug’s IBS-D treatment indications, Bausch Health intends to continue its vigorous defense of its IP rights while supporting the continued access to the drug for patients.

R. H.

Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.

Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève

Voir toutes les actualités de Bausch Health Companies Inc.